3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
3
NET
1
Gastrointestinal
1
CNS
1
Conditions
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
6
Stomach Neoplasms
4
Rectal Neoplasms
4
Gastro-enteropancreatic neuroendocrine tumor
4
Esophageal Neoplasms
4
Diarrhea
4
Weight Loss
3
Pancreatic Neoplasms
3
Neuroendocrine Tumors
3
Colonic Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Malnutrition
2
Duodenal Neoplasms
2
Vulvar Neoplasms
1
Vomiting
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatitis
1
Pancreatic Neuroendocrine Tumor G2
1
Pancreatic Intraductal Neoplasms
1
Nutrition Disorders
1
Neoplastic Cells, Circulating
1
Nausea
1
Liver Neoplasms
1
Intestinal Obstruction
1
Insulin Resistance
1
Interventions
lanreotide
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acromegaly
×
Octreotide
×
Gastrointestinal
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled